Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

897 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients.
de Jonge AV, van Werkhoven E, Dinmohamed AG, Nijland M, Zwinderman AH, Bossuyt PM, Veldhuis MS, Rutten EGGM, Mous R, Vermaat JSP, Sandberg Y, de Jongh E, Bilgin YM, Boersma R, Koene H, Kersten MJ, de Jong D, Chamuleau MED. de Jonge AV, et al. Among authors: de jongh e, de jong d. Blood Cancer J. 2023 May 22;13(1):85. doi: 10.1038/s41408-023-00854-2. Blood Cancer J. 2023. PMID: 37217463 Free PMC article.
Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment.
Glas AM, Kersten MJ, Delahaye LJ, Witteveen AT, Kibbelaar RE, Velds A, Wessels LF, Joosten P, Kerkhoven RM, Bernards R, van Krieken JH, Kluin PM, van't Veer LJ, de Jong D. Glas AM, et al. Among authors: de jong d. Blood. 2005 Jan 1;105(1):301-7. doi: 10.1182/blood-2004-06-2298. Epub 2004 Sep 2. Blood. 2005. PMID: 15345589 Free article.
Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).
Verdonck LF, Notenboom A, de Jong DD, MacKenzie MA, Verhoef GE, Kramer MH, Ossenkoppele GJ, Doorduijn JK, Sonneveld P, van Imhoff GW. Verdonck LF, et al. Among authors: de jong dd. Blood. 2007 Apr 1;109(7):2759-66. doi: 10.1182/blood-2006-07-035709. Blood. 2007. PMID: 17132720 Free article. Clinical Trial.
Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma.
Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, Wessels LA, van Laar R, van Krieken JH, Baars JW, Raemaekers J, Kluin PM, van't Veer LJ, de Jong D. Glas AM, et al. Among authors: de jong d. J Clin Oncol. 2007 Feb 1;25(4):390-8. doi: 10.1200/JCO.2006.06.1648. Epub 2007 Jan 2. J Clin Oncol. 2007. PMID: 17200149 Free article.
Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.
Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Calaminici M, Sander B, Thorns C, Campo E, Molina T, Lee A, Pfreundschuh M, Horning S, Lister A, Sehn LH, Raemaekers J, Hagenbeek A, Gascoyne RD, Weller E. Salles G, et al. Among authors: de jong d. Blood. 2011 Jun 30;117(26):7070-8. doi: 10.1182/blood-2011-04-345256. Epub 2011 May 2. Blood. 2011. PMID: 21536860 Free article. Clinical Trial.
Targetable genetic features of primary testicular and primary central nervous system lymphomas.
Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA. Chapuy B, et al. Among authors: de jong d. Blood. 2016 Feb 18;127(7):869-81. doi: 10.1182/blood-2015-10-673236. Epub 2015 Dec 23. Blood. 2016. PMID: 26702065 Free PMC article.
897 results